Prakt. lékáren. 2009; 5(6): 275-278

Pharmacotherapy of dyslipidemia

MUDr.Michal Vrablík, Ph.D., MUDr.Michaela Šnejdrlová
Centrum preventivní kardiologie, 3. interní klinika 1. LF UK a VFN, Praha

Pharmacotherapy of dyslipidemia is a corner stone of prevention of cardiovascular complications in high-risk patients. Best documented

lipid lowering agents are statins being used in monotherapy as well as the core of combination treatment regimens. Fibrates, ezetimibe,

resins and (in the Czech Republic still unavailable) niacin represent other treatment options of dyslipidemia. Complex intervention of

all lipid abnormalities using combination of different drug classes is a new approach to achieve further reduction of cardiovascular

atherothrombotic complications.

Keywords: statins, fibrates, ezetimibe, resins, niacin, cardiovascular risk, atherosclerosis

Published: December 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vrablík M, Šnejdrlová M. Pharmacotherapy of dyslipidemia. Praktické lékárenství. 2009;5(6):275-278.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Vaverková H, Soška V, Rosolová H, et al. Doporučení pro diagnostiku a léčbu dyslipidemií v dospělosti, vypracované výborem České společnosti pro aterosklerózu. Vnitr Lek 2007, 53(2): 181-197. Go to PubMed...
    2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4 444 pateints with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 334: 1383-1389. Go to original source...
    3. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis: The ASTEROID Trial. JAMA 2006; 295: 1556-1565. Go to original source... Go to PubMed...
    4. Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialist (CTT) Collaborators. Efficacy and safety of cholesterol lowering treatment: Prospective meta-analysis of data from 90 056 participants in 14 randomized trials of statins. Lancet 2005; 366: 1267-1278. Go to original source... Go to PubMed...
    5. Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006; 48: 438-445. Go to original source... Go to PubMed...
    6. Moghadasian MH. A safety look at currently available statins. Expert Opin Drug Saf 2002; 1: 269-274. Go to original source... Go to PubMed...
    7. Sica DA, Gehr TW. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and rhabdomyolysis: considerations in the renal failure patient. Curr Opin Nephrol Hypertens 2002; 11: 123-133. Go to original source... Go to PubMed...
    8. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002; 41: 343-370. Go to original source... Go to PubMed...
    9. Grundy SM, Vega GL, Yuan Z, et al. Effectiveness and Tolerability of Simvastatin Plus Fenofibrate for Combined Hyperlipidemia (The SAFARI Trial) Am J Cardiol 2005; 95: 462-468. Go to original source... Go to PubMed...
    10. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9 795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005; 366: 1849-1861. Go to original source... Go to PubMed...
    11. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation. 1992; 85: 37-45. Go to original source... Go to PubMed...
    12. Keech A, Fruchart JC, Brown W, et al. New data from the FIELD study: protecting the diabetic eye. Diab Vasc Dis Res 2007; 4(Suppl 4): 51-57. Go to original source...
    13. Sudhop T, Lutjohann D, Kodal A, et al. Inhibition of intestina cholesterol absorption by ezetimibe in humans. Circulation 2002; 106: 1943-1948. Go to original source... Go to PubMed...
    14. Kastelein JJP, Akdim F, Stoes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358(14): 1431-1443. Go to original source... Go to PubMed...
    15. Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008; 359: 1343-1356. Go to original source... Go to PubMed...
    16. Peto R, Emberson J, Landray M, et al. Analyses of cancer data from three ezetimibe trials. N Engl J Med 2008; 359: 1357-1366. Go to original source... Go to PubMed...
    17. Vrablík M. Reziduální riziko kardiovaskulárních příhod. Medicína po promoci 2009; 10: 60-64.
    18. Češka R. Cholesterol a ateroskleróza, léčba dyslipidémií. Praha: Triton 2005.
    19. The Lipid Research Clinics Coronary Prevention Trial Group. Results I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-364. Go to original source... Go to PubMed...
    20. Vrablík M, et al. Otazníky kardiovaskulární prevence 2009. Brno: FAMA, 2009: 158 s.

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.